PEGylation, proteins

Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54 459 -76... 

Fee CJ (2007) Size comparison between proteins PEGylated with branched and linear poly (ethylene glycol) molecules. Biotechnol Bioeng 98 725-731... 

Kubetzko S, Sarkar CA, Pliickthun A (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 68 1439-1454... 

A phase I/II study to evaluate the safety, immunogenicity, pharmacokinetics and potential efficacy of iv rhuTNF binding protein pegylated dimer in patients with active RA. Arthritis Rheum. 41, S58 (abstract). 

Veronese FM (2001) Peptide and protein PEGylation a review of problems and solutions. Biomaterials 22 405 -17... 

Pardridge WM, Wu D, Sakane T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm Res 1998 15 576-82. 

Piarris JM, Veronese PM, eds. Peptide and Protein PEGylation II—clinical evaluation. Adv Drug Deliv Rev 2003 55 1259-1350. 

Veronese FM, Harris JM Introduction and overview of peptide and protein pegylation, Adv Dmg Deliv Rev 2002, 54, 453-456. 

Veronese FM, Harris JM (Eds.) Special issue Peptide and protein PEGylation, Adv Dmg Del Syst 2002, 54, 453-609. 

Anytime the term process chemist is used, it usually relates to the development of a small synthetic molecule. However, there has been a growth explosion in the development of macromolecules as of late. These may include proteins, small molecules attached to proteins, pegylated proteins, DNA and RNA fragments, oligonucleotides, monoclonal antibodies, and even personalized medicines in vaccines being made from a specific patient to treat the same patient. As this is a growing trend within the pharmaceutical industry, the term process chemist should include development chemists who are involved in all of the above-mentioned areas. A major difference between these areas and the development of small molecules is that the process to manufacture these complex products usually defines the product versus the other way around for small molecules, where the product defines the process. 

Roberts, M.J., Bentley, MD., and Harris, J.M., Chemistry for peptide and protein PEGylation, Advanced Drug Delivery Reviews, 54, 459, 2002. 

Rosendahl, Mary S. Doherty, Daniel H. Smith, Darin J. Bendele, Alison M. Cox, George N. Site-specific protein PEGylation Application to cysteine analogs of recombinant human granulocyte colony-stimulating factor, BioProcess International (2005), 3(4), 52-56, 58-60, 62. 

Pee, C.J., Size-exclusion reaction chromatography (SERC) A new technique for protein PEGylation, Biotechnology Bioengineering, 82(2), 200, 2003. 

Kozlowski A, Harris J M (2001). Improvements in protein PEGylation Pegylated interferons for treatment of hepatitis C. J. Control Rel. 72 217-224. 

Moreland L W, McCabe D P, Caldwell J R, et al. (2000). Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J. Rheumatol. 27 601-609. 

---